References:
-
S. Cotofana, D. Freytag et. al. The Bidirectional Movement of the Frontalis Muscle: Introducing the Line of Convergence and it’s Potential Clinical Relevance. PRS 2020, May
-
J. Jankovic, J. Carruthers et. al. Neutralizing Antibody Conversion with OnabotulinumtoxinA From Global Studies Across Multiple Indications in Nearly 30,000 Patient Records: A Meta-analysis 2021, January
-
O. Ozgur, D Murariu et. al., Dry Eye Syndrome Due to Botulinum Toxin Type-A Injection: Guideline for Prevention. Hawaii Journal of Medicine and Public Health. 2012, May
-
E. Sorensen, C. Urman. Cosmetic Complications: Rare and Serious Events Following Botulinum Toxin and Soft Tissue Filler Administration. JDD, 2015, May
-
K.P. Bhakti, A. Munchau et. al., Generalised Muscular Weakness after Botulinum Toxin Injections for Dysonia: a report of 3 cases. J Neurol Neurogurg Psychiatry, 1999, 67
-
L. Bai, X. Peng et. al., Clinical Analysis of 86 Botulism Cases caused by Cosmetic Injection of Botulinum Toxin (BoNT), MD-Journal, 2018, 97
-
I.J. Moon, S. E. Chang, First Case of Anaphylaxis after Botulinum Toxin Type A Injection, Clinical and Experimental Dermatology, 2017, 42
-
L. Rosenfield, D. Kardassakis, The First Case Report of a Systemic Allergy to OnabotulinumA (Botox) in a Healthy Patient, Aesthetic Surgery Journal, 2014, vol.34
-
S. Dayan, Complications from Toxins and Fillers in the Dermatology Clinic-Recognition, Prevention and Treatment, Facial Plastic Surgery Clinic N Am, 2013, 663-673
-
T. Cote’, A. Mohan et. al., Botulinum Toxin Type A Injections: Adverse Events Reported to the US Food and Drug Administration in Therapeutic and Cosmetic Cases, Journal of the American Academy of Dermatology, 2005, Sept.
-
E. Yiannakopoulou, Serious and Long-Term Adverse Events Associated with the Therapuetic and Cosmetic Use of Botulinum Toxin, Pharmacology, 2015, 95